Abramov Dror Yosef 4

What Happened

• Dror Yosef Abramov, a director of Silexion Therapeutics Corp. (SLXN), received two grants on Feb 20, 2026: 9,091 fully vested restricted share units (RSUs) that were immediately settled for ordinary shares, and an award of options to purchase 10,685 ordinary shares. Both transactions are reported at $0.00 per share in the filing (total reported $0).

Key Details

• Transaction date: 2026-02-20; Form 4 filed 2026-02-23 (filed within the standard two-business-day window).
• RSUs: 9,091 shares granted and immediately settled for underlying ordinary shares (footnote F1).
• Options: 10,685 option awards granted (derivative). Vesting: they vest in full on the one‑year anniversary of grant and expire on the ten‑year anniversary (footnotes F2 & F3).
• Reported price/value: $0.00 per share for both rows (as shown on the Form 4).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Informational row: one row is included for informational purposes and reports no transaction effected (footnote F4).

Context

• The RSU grant settled immediately into shares (an outright acquisition of shares), while the option grant is a future right to buy shares that only vests in one year — it is not immediately exercisable. Grants and option awards by boards to directors are common compensation and do not by themselves imply a buy/sell signal; they increase the director’s future or current stake depending on settlement/vesting.